MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Institutional Ownership Changes & 13F Activity

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC 13F filings (Q1 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions among tracked filers. Notable filers include Renaissance Technologies LLC.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q1 2026Renaissance Technologies LLCBuy142,300276,772$5,159,030
Q4 2025Renaissance Technologies LLCBuy121,076134,472$1,772,341
Q3 2023Renaissance Technologies LLCSell-2,10413,396$764
Q2 2023Renaissance Technologies LLCSell-7,20015,500$791
Q1 2023Renaissance Technologies LLCBuy11,09122,700$486
Q4 2022Renaissance Technologies LLCBuy11,60911,609$122

Frequently asked questions about MLTX activity

  • Which institutional owners are buying MLTX?

    Institutional owners buying MLTX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in MLTX activity?

    "Buy" means an investor increased their reported position in MLTX compared to the prior reporting period. This reflects growing exposure to MOONLAKE IMMUNOTHERAPEUTICS (MLTX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in MLTX increasing?

    Institutional interest in MLTX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.

Related MLTX insights